Clinical Trial of AVL-3288 in Schizophrenia Patients
Status:
Completed
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase,
cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of
AVL-3288 each compared to placebo, in patients with schizophrenia.